1.82
-0.23(-11.22%)
Currency In USD
| Previous Close | 2.05 |
| Open | 2.28 |
| Day High | 2.33 |
| Day Low | 1.8 |
| 52-Week High | 6.9 |
| 52-Week Low | 1.5 |
| Volume | 608,611 |
| Average Volume | 129,924 |
| Market Cap | 4.7M |
| PE | -0.64 |
| EPS | -2.84 |
| Moving Average 50 Days | 2.49 |
| Moving Average 200 Days | 2.71 |
| Change | -0.23 |
If you invested $1000 in Creative Medical Technology Holdings, Inc. (CELZ) 10 years ago, it would be worth $0.22 as of January 14, 2026 at a share price of $1.82. Whereas If you bought $1000 worth of Creative Medical Technology Holdings, Inc. (CELZ) shares 5 years ago, it would be worth $16.7 as of January 14, 2026 at a share price of $1.82.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain
GlobeNewswire Inc.
Yesterday at 2:15 PM GMT
Data Show Strong Functional and Pain Improvements Supported by Excellent Safety ProfilePHOENIX, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biot
Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative
GlobeNewswire Inc.
Jan 06, 2026 2:15 PM GMT
PHOENIX, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company advancing regenerative medicine and AI-enabled biodefense solutions,
Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point
GlobeNewswire Inc.
Dec 17, 2025 2:15 PM GMT
Completion of Enrollment Positions CELZ for Near-Term Data Catalysts and Accelerates Path Toward Commercialization of a Transformative, Non-Opioid Therapy for Chronic Lower Back PainPHOENIX, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Creative Medical Techno